Tisotumab vedotin by Genmab for Metastatic Colorectal Cancer: Likelihood of Approval

Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer.

Related Keywords

Copenhagen ,Køavn ,Denmark ,Japan ,Netherlands ,Tisotumab Vedotin Tivdak ,Tisotumab Vedotin ,Globaldata Pharmaceutical Intelligence Center ,Metastatic Colorectal ,Metastatic Colorectal Cancer ,Phase Transition Success Rate Model ,Tissue Factor ,Pharmaceutical Intelligence ,